Tuesday, September 09, 2014 11:08:35 AM
Emesyl was developed by Dr. Charles Hensley who also developed Zicam, a homeopathic cold remedy that has been around since the mid-1990s. If the drug could have a fraction of the success of Zicam then investors in Itonis would stand to make tremendous gains.
With any company of this size there are considerable risks but the upside is huge. Matrixx Initiatives was the company that owned and marketed Zicam. In 2011 Matrixx was purchased by H.I.G. Capital for $8.75 a share, or a little over $75 million. A fraction of such a payoff might be worth the risk for this company.
LOVE ITNS
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM